TOBI: reducing the impact of pseudomonal infection.
作者信息
Govan John
机构信息
Department of Medical Microbiology, University of Edinburgh Medical School, Edinburgh EH8 9AG.
出版信息
Hosp Med. 2002 Jul;63(7):421-5. doi: 10.12968/hosp.2002.63.7.1987.
PMID:12187603
Abstract
Pseudomonas aeruginosa infection is associated with impaired lung function and reduced life expectancy in cystic fibrosis patients. Tobramycin nebulizer solution (TOBI, Chiron Corporation Ltd, Hounslow) has been specifically formulated for use against P. aeruginosa infection in the lung.
摘要
Zotero 插件